Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Subcutaneous immunoglobulin replacement in primary immunodeficiencies.

Melvin Berger1

  • 1School of Medicine, Case Western Reserve University, OH, USA. Melvin.Berger@CASE.edu

Clinical Immunology (Orlando, Fla.)
|June 23, 2004
PubMed
Summary

Subcutaneous immunoglobulin (IgG) infusion offers patient autonomy and fewer side effects compared to intravenous immunoglobulin (IVIg) therapy. This method may be preferable for select primary immunodeficiency patients despite dosing limitations.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hereditary angioedema C1-esterase inhibitor replacement therapy and coexisting autoimmune disorders: findings from a claims database.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2020
Same author

Antibodies to vaccine antigens in pooled polyclonal human IgG products.

Transfusion·2018
Same author

IgPro20, the Polyneuropathy and Treatment with Hizentra<sup>®</sup> study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG.

Immunotherapy·2018
Same author

Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies.

Journal of the peripheral nervous system : JPNS·2018
Same author

Primary immune deficiency diseases as unrecognized causes of chronic respiratory disease.

Respiratory medicine·2017
Same author

Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation.

Blood reviews·2017

Area of Science:

  • Immunology
  • Pharmacokinetics
  • Biologics Delivery

Background:

  • Subcutaneous immunoglobulin (IgG) infusion has been used for over 20 years for primary immunodeficiencies.
  • While intravenous immunoglobulin (IVIg) is more common in the US, subcutaneous IgG is widely used internationally.
  • Subcutaneous IgG offers distinct pharmacokinetic profiles compared to IVIg, with lower peaks and higher troughs.

Purpose of the Study:

  • To compare the pharmacokinetics, advantages, and disadvantages of subcutaneous IgG infusion versus intravenous immunoglobulin (IVIg) therapy.
  • To evaluate the suitability of subcutaneous IgG for patients with primary immunodeficiencies.
  • To identify obstacles and potential benefits of subcutaneous IgG replacement therapy.

Main Methods:

  • Review of pharmacokinetic differences between subcutaneous and intravenous immunoglobulin (IgG) administration.

Related Experiment Videos

  • Analysis of patient-reported outcomes and adverse effects associated with each route.
  • Consideration of logistical factors, including dosing frequency and vascular access requirements.

    • Main Results:

    • Subcutaneous IgG regimens result in lower peak and higher trough IgG levels compared to IVIg.
    • Advantages of subcutaneous IgG include enhanced patient autonomy, reduced systemic adverse effects, and no need for vascular access.
    • Disadvantages include limitations on infusion volume per administration, necessitating frequent dosing, and the need for reliable self-infusion capabilities.

    Conclusions:

    • Subcutaneous IgG replacement therapy presents a viable alternative to IVIg and intramuscular injections for carefully selected patients with primary immunodeficiencies.
    • The pharmacokinetic profile of subcutaneous IgG may be advantageous for certain patient populations.
    • Despite current regulatory obstacles in the US, subcutaneous IgG offers significant benefits in patient autonomy and tolerability.